In the endTB trial, researchers assessed the efficacy and safety of five 9-month, all-oral treatment regimens, as compared with the evolving standard of care, in participants with rifampin-resistant, fluoroquinolone-susceptible tuberculosis.
nej.md/3WFFJTv
#MedSky #IDSky